Cargando…

Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab

SIMPLE SUMMARY: Nivolumab (anti-PD-1 inhibitor) is the first monoclonal antibody approved for the treatment of NSCLC, with research results showing that patients who had received previous lines of therapy had a better response to this treatment and better overall survival. Tissue-level analyses fail...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monastirioti, Alexia, Papadaki, Chara, Kalapanida, Despoina, Rounis, Konstantinos, Michaelidou, Kleita, Papadaki, Maria A., Mavroudis, Dimitrios, Agelaki, Sofia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564103/ https://www.ncbi.nlm.nih.gov/pubmed/36230658 http://dx.doi.org/10.3390/cancers14194739

Ejemplares similares

A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer
por: Monastirioti, Alexia, et al.
Publicado: (2021)

MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer
por: Thomopoulou, Konstantina, et al.
Publicado: (2021)

Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy
por: Papadaki, Chara, et al.
Publicado: (2020)

MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer
por: Papadaki, Chara, et al.
Publicado: (2021)

TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications
por: Papadaki, Maria A., et al.
Publicado: (2022)

Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study
por: Rounis, Konstantinos, et al.
Publicado: (2021)

Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study
por: Rounis, Konstantinos, et al.
Publicado: (2023)

Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer
por: Michaelidou, Kleita, et al.
Publicado: (2020)

Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer
por: Papadaki, Chara, et al.
Publicado: (2019)

Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study
por: Rounis, Konstantinos, et al.
Publicado: (2021)

Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer
por: Papadaki, Maria A., et al.
Publicado: (2020)

Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer
por: Papadaki, Chara, et al.
Publicado: (2018)

Correction to: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer
por: Papadaki, Chara, et al.
Publicado: (2022)

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
por: Papadaki, Maria A, et al.
Publicado: (2020)

Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy
por: Kachris, Stefanos, et al.
Publicado: (2021)

Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a ‘Real-Life’ Setting
por: Skribek, Marcus, et al.
Publicado: (2020)

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Papadaki, Maria A., et al.
Publicado: (2021)

Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
por: Papadaki, Maria A., et al.
Publicado: (2022)

Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies
por: Rounis, Konstantinos, et al.
Publicado: (2022)

May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?
por: Psilopatis, Iason, et al.
Publicado: (2022)

Single-Cell RNA Sequencing Uncovers Heterogeneous Circulating Tumor Cell Subsets in Breast Cancer
por: Papadaki, Maria A., et al.
Publicado: (2022)

A new paradox for pCR in BRCA mutation carriers
por: Rounis, Konstantinos, et al.
Publicado: (2019)

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2015)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2011)

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer
por: Papadaki, Maria A, et al.
Publicado: (2014)

Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2009)

Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome
por: Polioudaki, Hara, et al.
Publicado: (2020)

Long Noncoding RNAs in Digestive System Malignancies: A Novel Class of Cancer Biomarkers and Therapeutic Targets?
por: Kladi-Skandali, Athina, et al.
Publicado: (2015)

Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy
por: Rounis, Konstantinos, et al.
Publicado: (2021)

Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016)

Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC
por: Hou, Jinpao, et al.
Publicado: (2016)

Prognostic role of microRNAs in breast cancer: A systematic review
por: Zografos, Eleni, et al.
Publicado: (2019)

Peripheral Blood MicroRNAs as Potential Biomarkers of Myocardial Damage in Acute Viral Myocarditis
por: Marketou, Maria, et al.
Publicado: (2021)

Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study
por: Papadaki, Chara, et al.
Publicado: (2020)

Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2019)

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study
por: Dimitrakopoulos, Foteinos-Ioannis, et al.
Publicado: (2022)

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_68cm7atlcdd2e0ej90co19b3q5